



Media Release

Blue Horizon announces Seed investment in Core Biogenesis

Zurich, 29 March 2022 – Blue Horizon, a pure play impact investor in the future of food, today announces its Seed investment in Core Biogenesis who use plants as biofactories to scale the production of high-value bioproducts like growth factors.

Blue Horizon invested in [Core Biogenesis](#), a French startup focusing on the production of growth factors for applications in both cell therapy and cultivated meat. Core Biogenesis' plant-based production platform has delivered several functional growth factors to date and provides unique cost-efficiency at large scale.

Functional, cost-efficient growth factors are key to unlocking mass production and commercialization of both cell therapies and cultivated meat. In both sectors, growth factors today constitute a major proportion of the cost of growth media, the nutrient solution cells are grown in. Furthermore, both sectors are projecting significant growth in the coming years, which will require larger amounts of growth factors than the current industry can supply. Lowering growth factor costs while increasing availability is thus pivotal to innovation in both pharma and food.

The current funding round will enable Core Biogenesis to expand the team that scales up production in a new facility in Strasbourg, France, while further developing their proprietary platform.

Friederike Grosse-Holz, Director at Blue Horizon, said: "The highly scalable and cost-effective production approach of Core Biogenesis can help unlock commercialization of both cell therapies and cultivated meat, enabling outstanding positive impact on humans, animals, and the planet. We are proud and excited to join Alexandre and his team on this exciting journey."

Alexandre Reeber, CEO of Core Biogenesis, said: "We are thrilled to be joined by Blue Horizon to help us accelerate the commercialization of our Bioproduction technology. With our shared mission to help make cell-based products profitable and mainstream for the benefits of human health and planetary health, we are fully aligned with the values and interests of Friederike and her team at Blue Horizon."

To date, Blue Horizon has invested in 60+ companies with a focus on protein alternatives and food tech. Some of the firm's recent investments include plant-based meat start-ups like Planted, Mosa Meat, which is developing tissue engineering technologies to mass produce affordable, cultured meat and AgBiome, the leader in developing innovative products from the Earth's microbial communities.

END



Media contact Blue Horizon

Marc Duceck
Head of Communications
Phone +41 79 639 42 38
media@bluehorizon.com

About Blue Horizon

Blue Horizon is accelerating the transition to a New Sustainable Food System that delivers outstanding returns for investors and the planet. The company is a global pioneer of the Future of Food. As a pure play impact investor, Blue Horizon has shaped the growth of the alternative protein and food tech market. The company invests at the intersection of biology, agriculture and technology with the aim to transform the global food industry. Blue Horizon was founded by Roger Lienhard in 2016 and is based in Zurich. To date, the company has invested in more than 60 companies. Its business model offers an attractive opportunity to invest in the evolution of the global food system while contributing to a healthy and sustainable world. www.bluehorizon.com

About Core Biogenesis

Core Biogenesis uses plants as biofactories to scale the production of high-value bioproducts. Our Ultra-scalable bioproduction as a service (UBaaS) platform accelerates mass production and increases yields, while driving down costs. By unlocking a new paradigm in recombinant protein production, we are helping build a more sustainable future. We believe that everything manufactured today will be biomanufactured tomorrow, and our technology unlocks this promise. Our first goal is to help democratize cellular agriculture and cell therapy by producing their key ingredients, recombinant growth factors and cytokines at a massive scale and orders of magnitude more cost-effectively.